Classificação em ações
#27149
Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in... Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in the discovery and advancement of therapeutic drugs. Based in Buffalo, New York, the organization maintains a modest workforce of 15 full-time employees. Its primary objective involves pioneering methods to stimulate the body's immune defenses to tackle significant medical challenges. A core component of its work is a platform utilizing Toll-like immune receptor activators, which demonstrates utility in both alleviating radiation-induced damage and in the field of immuno-oncology. The most advanced therapeutic candidate in its pipeline is Entolimod, an immune-stimulating compound currently under development as a protective measure against radiation exposure and as an immunotherapy for various cancers and other indications. The company's portfolio also encompasses other promising products, including CBLB612, Mobilan, and CBL0137. CBLB612 is formulated from a natural stimulant that targets a specific component of the innate immune system: the heterodimeric receptor formed by toll-like receptors 2 (TLR2) and 6 (TLR6). Mobilan is a recombinant, non-replicating adenovirus engineered to induce the expression of TLR5 and its corresponding agonistic ligand. Lastly, CBL0137 is a small molecule characterized by a multi-faceted mechanism of action, suggesting its potential effectiveness across diverse forms of cancer.
Preço da ação
$3.17
Última sincronização: 2021-08-31
Negociar Cytocom, Inc. (CBLI)
Lucros da Cytocom, Inc. (CBLI)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Cytocom, Inc., os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Cytocom, Inc. de 2026 a 2026
Lucros no final de cada ano
| Ano |
Lucros |
Alterar |
|
Não há dados suficientes para as datas fornecidas. |
Lucros de empresas semelhantes ou concorrentes
| Empresa |
Lucros |
Diferença de Lucros |
País |
|
|
$5.27B |
-
|
US
|
|
|
$-3.09B |
-
|
US
|
|
|
$1.95B |
-
|
NL
|
|
|
$1.61B |
-
|
AU
|
|
|
- |
-
|
CH
|
